RxDoctor Payments Data

Shaun Helmhout, MD

Family Medicine · Oxford, MSNPI 1851308480

Payments from drug & device makers

$9,092in general payments, 2019–2025

Across 594 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$790
  • Novo Nordisk$691
  • Amgen$657
  • Boehringer Ingelheim$517
  • Livanova USA, Inc.$510
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$9,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,092 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$311,142
Medicare patients
756
Services billed
9,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide13$189,292
OzempicSemaglutide95$103,829
JardianceEmpagliflozin95$96,670
ProliaDenosumab29$52,907
FycompaPerampanel39$48,725
FarxigaDapagliflozin Propanediol44$41,813
LinzessLinaclotide61$39,013
EliquisApixaban51$38,580
XcopriCenobamate12$29,246
XareltoRivaroxaban31$24,056
MounjaroTirzepatide20$23,228
NuedextaDextromethorphan Hbr/Quinidine12$19,519
ShingrixVaricella-Zoster Ge/As01b/Pf84$18,845
VascepaIcosapent Ethyl37$18,688
Synjardy XrEmpagliflozin/Metformin Hcl17$13,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$257$213,34844 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$517$119,153124 claims
Novo NordiskOzempic$691$103,82995 claims
AmgenProlia$657$52,90729 claims
PfizerEliquis, Abrysvo$266$48,44284 claims
AbbVieLinzess, Synthroid$1,254$42,14799 claims
AstraZenecaFarxiga$790$41,81344 claims
GSKShingrix, Anoro Ellipta$115$26,44696 claims
Lilly USA, LLCMounjaro$364$23,22820 claims
MerckJanuvia, Gardasil 9$56$14,26225 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$194$9,21511 claims
Genentech USA, Inc.Xofluza$15$7,01130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →